IMARA Inc. (IMRA)
Stock Price:
$23.11 USD
-2.14 (-8.48%)
Updated Sep 21, 2020 2:25 PM EDT - Market open
Key Info
| Market Cap |
400.37M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
17.32M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 21, 2020 |
| Last Price |
$23.11 |
| Previous Close |
$25.25 |
| Change ($) |
-2.14 |
| Change (%) |
-8.48% |
| Day's Open |
24.92 |
| Day's Range |
23.04 - 25.25 |
| Day's Volume |
333,732 |
| 52-Week Range |
13.40 - 62.71 |
More Stats
| Market Cap |
400.37M |
| Enterprise Value |
294.10M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
17.32M |
| Float |
7.93M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
127,385 |
| Short Ratio |
3.22 |
| Short % of Float |
3.80% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.98 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
106.28M |
| Net Cash / Share |
6.13 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-25.46% |
| ROE |
-42.16% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$41.33*
(78.84% upside)
Low
30.0
Current: $23.11
High
59.0
Target: 41.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -24.12 | -10.68 |
| Net Income | -23.46 | -11.34 |
| Shares Outstanding | 0.70 | 0.70 |
| Earnings Per Share | -33.40 | -16.14 |
| Operating Cash Flow | -21.88 | -8.78 |
| Capital Expenditures | -0.14 | - |
| Free Cash Flow | -22.02 | -8.78 |
| Cash & Equivalents | 28.91 | 7.38 |
| Net Cash / Debt | 28.91 | 7.38 |
| Assets | 33.30 | 7.71 |
| Liabilities | 4.38 | 1.83 |
| Book Value | -48.85 | -26.32 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
IMARA Inc. |
| Country |
United States |
| Employees |
16 |
| CEO |
Rahul D. Ballal |
Stock Information
| Ticker Symbol |
IMRA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMRA |
| IPO Date |
March 12, 2020 |
Description
Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.